Table TDI-36. Primary amphetamine use among new clients entering treatment (%), 2003 to 2009

Country		2004	2005	2006	2007	2008	2009
Bulgaria		0.7	1.8	2.7	2	6.5	3.5
Czech Republic		58.4	59.7	61.7	63.6	62.7	63.1
Denmark		12.9	10.2	14.9	13.5	14.2	12.2
Germany		9.4	9.7	10	10.4	10.6	10.3
Estonia		:	:	:	:	4.5	6.4
Ireland		0.9	1.1	0.9	1	1	0.6
Greece		0	0	0	0	0.1	0
Spain		1	1.1	1.2	1.2	1	:
France		:	0.2	0.3	0.3	0.3	0.2
Italy		0.1	0.1	0.2	0.1	0.3	0.1
Cyprus		0	0.5	0	0	0	0.3
Latvia		24.5	22.6	22.3	24	24.5	29
Lithuania		2.4	4.9	4.3	6.6	4.8	4.3
Luxembourg		0	0.4	0.6	0.3	0.3	0.3
Hungary		4.4	5.6	5.3	10.2	9.8	9.7
Malta		0.7	0	0	:	:	0
Netherlands		6	7	7.5	6.9	7.1	6.1
Austria		:	:	2.5	2.8	1.8	2.5
Portugal		:	0	0.2	0.1	0	0
Romania		0.4	0.2	0.5	0.2	0.3	0.3
Slovenia		0.2	0.6	0.3	0	0	0.8
Slovakia		31.6	30.1	32.2	33.2	39.1	34.6
Finland		28	27.6	22	22.9	24.4	18.8
Sweden		27.7	32.7	33	27.7	24.8	18.1
United Kingdom		5.1	4.1	3.9	4.5	4.4	3.8
Croatia		:	:	0	7	2	3.3
Turkey		0	0.1	0	0	0.1	0

Notes:

 : Indicates no data are available               

 Percentages are of new clients with known primary drug.               

 Only countries with available data are shown               

 See also ‘General notes for interpreting data’ on the Explanatory notes and help page.   

Sources:

 Reitox national reports 2010 — Standard table 34 See also Table TDI-4 and Table TDI-5 and see Table TDI-0] for details on sources.   

• Download this data in Excel (.xls) format

(see the help page for information about formats etc.)